Companies / Australia
Cervarix Receives First Approval
May 2007 | Industry NewsUK-based drugmaker GlaxoSmithKline (GSK)'s cervical cancer vaccine Cervarix has been approved in Australia, its first major market. This news is a bright note for GSK after the company recently experienced a sharp fall in share prices due to concerns over the safety of blockbuster diabetes drug Avandia.
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
